Inferra AIResearch Tools

Inferra AI / Company / JNJ

Johnson & Johnson

JNJ · Health Care

Last earnings Oct 13, 2026

Key results

Shockwave International revenuequarter

$20M

sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) Shockwave International revenue includes $20M of sales that should be reflected in the U.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

AI analysis

Q3 2025 · reported Oct 14, 2025

Based on: Earnings release + parent 8-K — transcript not held

Shockwave International revenue · Q3 2025
$20M
EX-99 · Oct 14, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Shockwave International revenue$20M——

EX-99 · Oct 14, 2025

Guidance · company-stated

Direction: raised

No guidance located in the held release

Stated figure4%

“4% at the midpoint and increasing adjusted EPS* guidance by $0.”

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Johnson & Johnson Q3 2025 — sales (5) Acquired with Intra-Cellular Therapies on April 2, 2025 (6) Due to the timing of the integration of the US and foreign affiliates in the year of acquisition (2024), prior quarter (Q3 2024) S…

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

Note to investors concerning forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things future operating and financial performance, product development, and market position and business strategy.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

Risks & headwinds

Full-year 2025 guidance Johnson Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson Johnson.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson Johnson s most recent Annual Report on Form 10-K, including in the sections captioned Cautionary Note Regarding Forward-Looking Statements and Item 1A.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters).

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry.

SEC original ↗Johnson & Johnson — Earnings release (8-K exhibit)EX-99Oct 14, 2025

Documents

Earnings deck slides

1 deck with slide view

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

77 documents

Earnings releases

39 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Johnson & Johnson are held in this edition of the library.

Mentioned by

11 companies

Other tracked companies whose held documents mention Johnson & Johnson by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.